Health Care • Medical/Dental Instruments
$127.80 ▲ +3.81
(+3.07%)
MKT CAP: $4.21B • VOL: 550.3K
52W L $101 52W H $192
IRTC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $747.1M | $591.8M | $492.7M |
| YoY Revenue Growth % | +26.2% | +20.1% | — |
| Gross Profit | $527.3M | $407.5M | $216.8M |
| Gross Margin % | 70.6% | 68.9% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$57.4M | -$115.5M | -$125.2M |
| Operating Margin % | -7.7% | -19.5% | -25.4% |
| Net Income (GAAP) | -$45.0M | -$113.0M | -$123.0M |
| EBITDA (Normalized) | -$20.3M | -$88.4M | -$107.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $80.9M | $3.4M | -$50.1M |
| Capital Expenditures (CapEx) | $46.3M | $33.9M | $22.2M |
| Free Cash Flow (FCF) | $34.5M | -$30.6M | -$72.3M |
| FCF Margin % | 4.6% | -5.2% | -14.7% |
| Return on Invested Capital (ROIC %) | -14.8% | -45.0% | -7.1% |
| Cash & Short-Term Equivalents | $236.0M | $419.6M | $254.9M |
| Total Debt (Short + Long Term) | $390.3M | $378.2M | $542.2M |
| Total Stockholders' Equity | $152.7M | $90.9M | $1.11B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IRTC.